Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: A systematic review and Bayesian approach network meta-analysis

European Heart Journal

Volumn 35, Issue 17, 2014, Pages 1147-1158

  Kang, Si Hyuck ^a   Park, Kyung Woo ^a   Kang, Do Yoon ^a   Lim, Woo Hyun ^a   Park, Kyung Taek ^a   Han, Jung Kyu ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Oh, Byung Hee ^a   Park, Young Bae ^a   Kandzari, David E ^b   Cohen, David J ^c   Hwang, Seung Sik ^d   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

^b PIEDMONT HEART INSTITUTE   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^d Inha University School of Medicine   (South Korea)

Author keywords

Bare metal stents; Biodegradable polymer drug eluting stents; Drug eluting stents; Meta analysis

Indexed keywords

PACLITAXEL; RAPAMYCIN; UMIROLIMUS; ZOTAROLIMUS; EVEROLIMUS; TUBULIN MODULATOR;

BARE METAL STENT; BAYES THEOREM; BIODEGRADABLE POLYMER BIOLIMUS ELUTING STENT; BIODEGRADABLE POLYMER DRUG ELUTING STENT; COBALT CHROMIUM EVEROLIMUS ELUTING STENT; DEVICE SAFETY; DRUG ELUTING STENT; DURABLE POLYMER DRUG ELUTING STENT; ENDEAVOR ZOTAROLIMUS ELUTING STENT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MEDICAL DEVICE COMPLICATION; META ANALYSIS; PACLITAXEL ELUTING STENT; PLATINUM CHROMIUM EVEROLIMUS ELUTING STENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOLUTE ZOTAROLIMUS ELUTING STENT; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIROLIMUS ELUTING STENT; STENT THROMBOSIS; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; COMPARATIVE STUDY; MYOCARDIAL INFARCTION; PROCEDURES; PROSTHESIS FAILURE; STENT;

ABSORBABLE IMPLANTS; BAYES THEOREM; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; PROSTHESIS FAILURE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; STENTS; TUBULIN MODULATORS;

EID: 84900023527     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht570     Document Type: Review

References (32)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231
3. Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S, European Association for Percutaneous Cardiovascular I, Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, SerruysPW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-2555
4. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in Drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-1521
5. Pfisterer M, Brunner-La RoccaHP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C, Investigators B-L. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48: 2584-2591
6. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should webe cautious?. Circulation 2004;109:701-705
7. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202
8. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 2008;118:1138-1145
9. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabate M, Kim HS, DeWaha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-Analysis. Lancet 2012;379:1393-1402
10. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J. Short- And long-Termoutcomes with drug-eluting and bare-metal coronary stents: A mixed-Treatment comparison analysis of 117,762 patient-years of follow-up from randomized trials. Circulation 2012;125:2873-2891
11. ParkKW, Kang SH, Velders MA, Shin DH, Hahn S, Lim WH, Yang HM, Lee HY, Van Boven AJ, Hofma SH, Kang HJ, Koo BK,OhBH, Park YB, Kandzari DE, Kim HS. Safety and efficacy of everolimus- versus sirolimus-eluting stents: A systematic review and meta-Analysis of 11 randomized trials. Am Heart J 2013;165:241-250 e4
12. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301
13. Meredith IT, Verheye S, Dubois CL, Dens J, Fajadet J, Carrie D,Walsh S, Oldroyd KG, Varenne O, El-Jack S, Moreno R, Joshi AA, Allocco DJ, Dawkins KD. Primary endpoint results of the EVOLVE trial: A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol 2012;59: 1362-1370
14. Kereiakes DJ, Cannon LA, Feldman RL, Popma JJ, Magorien R, Whitbourn R, Dauber IM, Rabinowitz AC, Ball MW, Bertolet B, Kabour A, Foster MC, Wang JC, Underwood P, Dawkins KD. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: Primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of theTAXUSElement Paclitaxel-Eluting Coronary Stent System) trial. J Am Coll Cardiol 2010;56:264-271
15. Kelbaek H, Thuesen L, Helqvist S, Clemmensen P, Klovgaard L, Kaltoft A, Andersen B, Thuesen H, Engstrom T, Botker HE, Saunamaki K, Krusell LR, Jorgensen E, Hansen HH, Christiansen EH, Ravkilde J, Kober L, Kofoed KF, Terkelsen CJ, Lassen JF, Investigators D. Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: Eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 2008;118:1155-1162
16. Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schomig A, Kastrati A, Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts I. Drug-eluting versus baremetal stents in saphenous vein graft lesions (ISAR-CABG): A randomised controlled superiority trial. Lancet 2011;378:1071-1078
17. Wang B, Han YL, Jing QM, Wang SL, Ma YY, Wang G, Luan B, Li Y, Wang ZL, Wang DM. Therapeutic effect and safety of drug eluting stent for patients with acute ST-elevation anterior wall myocardial infarction by left anterior descending artery occluded abruptly. Zhonghua Yi Xue Za Zhi 2010;90:2099-2102
18. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaborations 2011, available from http://www.cochrane-handbook.org/.
19. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research C. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351
20. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-3124
21. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci 1992;7:457-472
22. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL,Giddings VL, Coleman L,WongGK, Edelman ER. Stent thrombogenicity early inhigh-risk interventional settings isdrivenby stentdesignanddeployment andprotected by polymer-drug coatings. Circulation 2011;123:1400-1409
23. StoneGW, Rizvi A,NewmanW, Mastali K,Wang JC, Caputo R,Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362: 1663-1674
24. Kedhi E, Joesoef KS, McFadden E,Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010;375:201-209
25. Sabate M,Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gomez-Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012;380:1482-1490
26. de Waha A, Cassese S, Park DW, Burzotta F, Byrne RA, Tada T, King LA, Park SJ, Schomig A, Kastrati A. Everolimus-eluting versus sirolimus-eluting stents: An updated meta-Analysis of randomized trials. Clin Res Cardiol 2012;101:461-467
27. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, WijnsW, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 2008; 372:1163-1173
28. Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K-E, Wijns W, Schuler G, Fath-Ordoubadi F, Worthley S, Thuesen L, Meredith IT, Bressers M, Nagai H, Paunovic D. Randomised comparison of NoboriTM, biolimus A9-eluting coronary stent with a Taxusw, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The Nobori 1 trial. EuroIntervention 2007;2:426-434
29. Raber L, Kelbaek H, Ostojic M,Baumbach A,Heg D, Tuller D, vonBirgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Luscher TF, Taniwaki M, Matter CM, Meier B, Juni P, Windecker S. Effect of biolimus-eluting stents with biodegradable polymer vs baremetal stents on cardiovascular events among patients with acute myocardial infarction: The COMFORTABLE AMI randomized trial. JAMA 2012;308:777-787
30. Lupi A, Rognoni A, Secco GG, Lazzero M, Nardi F, Fattori R, Bongo AS, Agostoni P, Sheiban I. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: Insights from a meta-Analysis of 5834 patients. Eur J Prev Cardiol 2012; [Epub ahead of print].
31. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, WijnsW, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Juni P. Long-Term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011;378:1940-1980
32. Windecker S, Witzenbichler B, Stangl K, Slagboom T, Neumann F-J, Lefévre T, Ruiz-Salmeron R, Sabaté M, Piot C, Richardt G, Merkely B, Goicolea J, Bilger J, Schneider H, Barragan P, Cook S, Erne P,Waksman R, Haude M. Safety and clinical performance of the drug- eluting orsiro stent in the treatment of subjects with single de novo coronary artery lesions-II (BIOFLOW-II). EuroPCR 2013; Paris; 2013